Physician profile
Clive Miranda
NPI 1699304352
$2,181.51
in general payments reported to CMS, 2019-2025
13 companies · $1,712 in 2025
The $1,712 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $470 · 2025: $1,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,181.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $349.06 | 2024-2025 | Entyvio, Eohilia |
| Abbvie INC. | $338.56 | 2025 | Creon, Skyrizi, Rinvoq |
| Genzyme Corporation | $313.38 | 2024-2025 | |
| Ardelyx, INC. | $290.32 | 2024-2025 | Ibsrela |
| Boston Scientific Corporation | $209.28 | 2024-2025 | Resolution 360 Clip |
| Lilly USA, LLC | $193.54 | 2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.60 | 2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $91.49 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $74.68 | 2025 | Iqirvo |
| Pfizer INC. | $65.58 | 2024-2025 | |
| Novo Nordisk INC | $32.51 | 2025 | Wegovy |
| Organon LLC | $22.36 | 2025 | Hadlima |
| Phathom Pharmaceuticals, INC. | $16.15 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clive Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.